Q2 2024 EPS Estimates for Indivior PLC (NASDAQ:INDV) Lowered by Analyst

Indivior PLC (NASDAQ:INDV) – Investment analysts at Northland Capmk lowered their Q2 2024 EPS estimates for Indivior in a research note issued on Monday, July 1st. Northland Capmk analyst C. Byrnes now expects that the company will post earnings of $0.38 per share for the quarter, down from their previous forecast of $0.46. The consensus estimate for Indivior’s current full-year earnings is $2.00 per share. Northland Capmk also issued estimates for Indivior’s Q3 2024 earnings at $0.43 EPS and Q4 2024 earnings at $0.55 EPS.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, April 25th. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.01). Indivior had a net margin of 0.44% and a return on equity of 842.72%. The company had revenue of $284.00 million for the quarter, compared to analysts’ expectations of $300.00 million.

Separately, Craig Hallum started coverage on shares of Indivior in a report on Wednesday, April 3rd. They set a “buy” rating and a $37.00 price objective for the company.

Indivior Stock Down 0.1 %

INDV opened at $15.26 on Tuesday. The company has a quick ratio of 0.74, a current ratio of 0.92 and a debt-to-equity ratio of 23.50. The firm has a 50 day moving average price of $17.11 and a 200-day moving average price of $18.07. Indivior has a twelve month low of $14.38 and a twelve month high of $24.90. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of 1,526.00 and a beta of 0.69.

Institutional Trading of Indivior

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FourWorld Capital Management LLC bought a new position in shares of Indivior in the first quarter worth approximately $2,215,000. Janus Henderson Group PLC boosted its position in shares of Indivior by 14.2% in the first quarter. Janus Henderson Group PLC now owns 440,121 shares of the company’s stock worth $9,424,000 after purchasing an additional 54,750 shares during the period. Quadrature Capital Ltd bought a new position in shares of Indivior in the first quarter worth approximately $1,523,000. Toronto Dominion Bank boosted its position in shares of Indivior by 58.0% in the first quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock worth $44,872,000 after purchasing an additional 769,000 shares during the period. Finally, M&G Plc bought a new position in shares of Indivior in the first quarter worth approximately $2,518,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.